Tergus is more than a team of people, it is a family. We believe in understanding each individual’s requirements and provide them with the opportunity to learn and grow. Employees are encouraged to engage in continuous learning and be ahead of the curve. Training is provided on a regular basis to facilitate professional growth. Our focus is to learn every day and produce quality work. In addition to maintaining strong technical acumen, Tergus peers guide each other every step of the way. We have key people in each business unit who work towards making Tergus a leader in topical product development.
Sr. Director Human Resources & Organization Effectiveness
Duffy leads the human resource and organization effectiveness strategy with Tergus. In this capacity, the core focus aligns human resources with the business strategy. This alignment focuses on turning Tergus’ human resources into a sustainable competitive advantage to optimize organizational effectiveness and deliver operational excellence and value creation for Tergus’ customer base.
The human resource systems deployed in this process are:
- Talent identification and capabilities assessment
- Leadership and workforce development
- Encouraging cross function communication and collaboration
- Performance measurement, reward and recognition systems for high performance
- Total compensation and benefits
- Succession planning
This systems focus will ensure that Tergus continues to be an employer of preference and world-class in its competitive market space.
Duffy began his career with the 3M Company in manufacturing, quality systems, and human resources. His most recent experience was with LipoScience of Raleigh, NC, an in-vitro diagnostic cardiovascular test, technology platform, and CRO. During his twelve years with LipoScience, Duffy provided leadership in human resources, laboratory operations and quality assurance and regulatory systems. LipoScience was acquired by the Laboratory Corporation of America in 2014.
Sr. Director Quality Assurance
Dawn is a seasoned professional with 33 years of extensive experience in Quality, Regulatory and Compliance in the pharmaceutical industry. In her role as Senior Director, Quality Assurance, Dawn will provide executive leadership and direction to the Quality Assurance functions at the Tergus RTP and Kannapolis sites. Her experience spans pharmaceutical, cosmetics and over-the-counter products working for large international pharma and for CMO’s. Dawn is committed to creating and nurturing a strong Quality culture that focuses on systems thinking, protecting assets and ensuring adherence to regulatory requirements.
Dawn began her 31-year career at GSK as a chemist/scientist in the Quality labs in roles of increasing responsibilities followed by experience in CMC, Global Regulatory Affairs, Import/Export Compliance; DEA Compliance Management. Prior to joining Tergus Pharma, her most recent role at was as Director, Regulatory Compliance at Mayne Pharma and included oversight of Documentation Management, Vendor and Client Audits and support of Regulatory Agency inspections. Dawn received a B.S. in Chemistry from Lee University in Cleveland, Tennessee.
In her spare time, Dawn enjoys spending time fishing in the rivers of Eastern North Carolina and ocean with her husband, relaxing in the beautiful Blue Ridge Mountains of NC, working out, and volunteering to support disabled veterans.
Dr. Nalamothu is CEO & Co-Founder of Tergus Pharma and has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace.
After earning his Ph.D. in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.
Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.
Alon serves as a Skin Biology Scientist III with the responsibility of conducting various studies and developing novel assays using ex-vivo human skin models. Such experiments include validation of target engagement, skin irritation testing, effects on pigmentation and more. Alon brings over 13 years of practical knowledge of human skin structure, function, and pathology. His previous work in academic settings focused on the investigation of molecular processes that regulate human skin barrier, phototoxicity, inflammation, skin cancer, hair loss, and abnormal scars.
Prior to joining EnDev/Tergus, Alon received his training in skin biology at the department of dermatology at the University of Rochester, NY, and served as a Research Associate at Hampton University Skin of Color Research Institute in Virginia.
Alon earned a bachelor’s degree in Biotechnology Engineering in Israel and a Ph.D. in Pharmacology from the University of Rochester, NY. His work on human skin function and disease has been published in top journals and received several awards and recognition from his peers.
In Bethany’s experience with Tergus Pharma, project management and workflow are the key components to leading the IVRT team. Working with the IVRT team has taught her how a successful group of people can work in concert with one another to achieve quality and compliance together.
With over 15 years of experience in Pharmaceutical Chemistry, Bethany began her career as a QC Chemist running stock methods for stock products in large Pharma. For the last 10 years, she has spent her career in CROs which lent her the ability to learn about and analyze multiple forms of pharmaceutical dosing.
Justine joined EnDev in June 2017 as an Analytical Data Auditor. Her knowledge of laboratory practices and GMP environments quickly moved her to the position of Analytical Scientist II. As an Analytical Scientist II she works with Formulation Development and clients to develop and validate analytical methods. Previously to joining EnDev, Justine worked as a Research and Development Chemist at Mylan Pharmaceuticals in Morgantown, West Virginia. Justine graduated from Ursinus College with a B.S. in Chemistry. Outside of work, Justine enjoys playing soccer, snowboarding, mountain biking, and spending time outdoors.
James has worked in the pharmaceutical industry for 7 years and currently holds the position of Analytical Scientist II at the Kannapolis site. He primarily works on analytical method development and validation in support of formulation development projects. Prior to joining EnDev and Tergus James was a Team Leader in the Method Development and Validation group at Mayne Pharma in Greenville, NC. His focus there was supporting customer projects from early phase formulation development through to commercial manufacturing. A big emphasis in James’ time there was to develop phase appropriate approaches to method validation in order to streamline projects for our customers. Outside of work he enjoys running, mountain biking, skiing and travelling.
Dr. Thakker is Co-Founder Emeritus of Tergus and is a pioneer in functional testing for semi-solids. Under her leadership, Tergus has emerged as the recognized global leader in developing release rate methods for semi-solid dosage forms.
She was involved in the development of in Vitro Release Testing (IVRT), recognized as an essential testing protocol for Semi-solid dosage forms. Her work led to the development of the SUPAC-SS guidance document that the pharmaceutical industry follows. She was also a member of the USP’s Advisory Panel from 2010-2015, and helped draft chapters 3 and 1724, and also a member of USP’s Expert Committee on Dosage forms.
Dr. Thakker earned her PhD in Pharmaceutical Chemistry at the University of Kansas. She worked at US Pharmacopeia for 12 years, where she specialized in the development and validation of dissolution methods in the Drug Research and Testing Laboratory. Dr. Thakker has also held leadership positions at Sphinx Pharmaceuticals and BioAnalytika Laboratories.
With the emergence of newer, alternative dosage forms over the past 10 years, she has surfaced as a well-recognized global leader in the development of topical drug products, providing expertise in the development and validation of performance tests used to evaluate the transport of drugs across skin and other membranes (e.g., buccal, sublingual, vaginal, rectal). Working with compendial and regulatory organizations, Dr. Thakker continues to strive toward improving public standards for topical and other dosage forms.
Ravi leads a team of analytical scientists on multiple projects for providing pre-formulation/formulation support with studies including solubility, Drug-Excipient Compatibility, DOE, and prototype stabilities. He is an analytical point of contact for clients and represent the group in client meetings. He is very proficient in the development of stability-indicating HPLC methods, phase-appropriate validations, and method transfers to support topical drug product development. Apart from early R&D, his team occasionally provides support for GLP/GMP manufacturing campaigns with release and stability.
He has a Master’s degree in Pharmaceutical Sciences from Campbell University with a focus in Industrial Pharmacy. He was inducted in Rho-Chi Pharmaceutical Honor Society for his academic excellence. With his pharmaceutical background, he takes interest in formulation development as well.
Outside work, Ravi is a foodie, plays ping-pong and an aspiring runner. He loves to travel and learn about different cultures.
Srikanth Manne works as Principal Scientist at Tergus Pharma leading a team with a focus towards development of various Topical dosage forms in branded NCE and complex Topical Generic formulations. He is an expert in materializing the design of experiments, QbD and in the development of the strategies for biowaiver during the development of formulations.
He has over 10 years of experience in formulation and development of 505(b)(2) and complex generics (ANDA), having been associated with Dermatology R&D, Dr. Reddys Laboratories and Martindale Pharma.
Srikanth Manne obtained his Masters in Industrial Pharmaceutics from University of Greenwich and Bachelors in Pharmacy from India.
Tammy leads the Analytical and R&D team and ensures that they consistently produce accurate, sound analytical data by inspiring them to execute laboratory analyses precisely and efficiently in accordance with GMP/GLP standards. She comes to Tergus with 12+ years of experience in analytical services and method development/validation in the pharmaceutical contract manufacturing industry providing strong leadership to drive quality results.
Tammy earned a B.S in Chemistry from the University of Houston and began pursuing a fast-growing career in the pharmaceutical industry. Her continuous drive to help others by providing mentorship, fostering academic growth and excellence in the scientific community has made her a tremendous asset.